title: Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report.
abstract: BACKGROUND
  The purpose of this study was to elucidate the effects of glimepiride on the levels of biomarkers related to cardiovascular regulation in patients with type 2 diabetes mellitus.
  
  
  RESULTS
  Thirty-four patients with type 2 diabetes received glimepiride for 24 weeks. Significant decreases in the levels of glyceraldehyde-derived advanced glycation end products, (glycer-AGE: toxic AGE), eotaxin and fibroblast growth factor (FGF)-2 were recognized after the administration of glimepiride. Moreover, there were trends for there to be increases in the levels of granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage-colony stimulating factor (GM-CSF), and decreases in the levels of fractalkine, soluble CD40 ligand (sCD40L), macrophage inflammatory protein (MIP)-β, vascular endothelial growth factor (VEGF) and soluble receptor for AGE (sRAGE).
  
  
  CONCLUSIONS
  Glimepiride may have potent anti-oxidative, anti-inflammatory and angiogenic properties and it may potentially repair tissue damage by decreasing the levels of toxic AGE and increasing colony-stimulating factors.
authors.forename: Ikuko
authors.initials: I
authors.lastname: Nakamura
authors.affiliation: Department of Cardiovascular Medicine, Saga University, Saga 849-8501, Japan. junoyama@cc.saga-u.ac.jp.
authors.forename: Jun-ichi
authors.initials: J
authors.lastname: Oyama
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Komoda
authors.forename: Aya
authors.initials: A
authors.lastname: Shiraki
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Sakamoto
authors.forename: Isao
authors.initials: I
authors.lastname: Taguchi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Hiwatashi
authors.forename: Aiko
authors.initials: A
authors.lastname: Komatsu
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Takeuchi
authors.forename: Sho-ichi
authors.initials: S
authors.lastname: Yamagishi
authors.forename: Teruo
authors.initials: T
authors.lastname: Inoue
authors.forename: Koichi
authors.initials: K
authors.lastname: Node
mesh_terms: D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D038321:Glycemic Index / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013453:Sulfonylurea Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; C057619:glimepiride